| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Axonal Neuropathy, Serum
MessageSendout, Mayo test code: AIAES
Test Code
LAB1238016
Alias/See Also
Autoimmune Neuropathy
Peripheral Neuropathy
Neuropathy
Axonal Neuropathy
Small fiber neuropathy
Sensory Ganglionopathy
Autonomic neuropathy
Polyradiculopathy
AIAES
Peripheral Neuropathy
Neuropathy
Axonal Neuropathy
Small fiber neuropathy
Sensory Ganglionopathy
Autonomic neuropathy
Polyradiculopathy
AIAES
CPT Codes
86255x11, 84182
Includes
If the indirect immunofluorescence assay (IFA) patterns suggest antiglial nuclear antibody-1 (AGNA-1), then AGNA-1 antibody IFA titer and AGNA-1 antibody immunoblot will be performed at an additional charge.
If the IFA patterns suggest antineuronal nuclear antibody type 1 (ANNA-1), then ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-3 antibody, then ANNA-3 IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then PCA-1 antibody IFA titer and PCA-1 antibody immunoblot will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then PCA-2 antibody IFA titer will be performed at an additional charge.
If the IFA patterns suggest amphiphysin antibody, then amphiphysin antibody IFA titer and amphiphysin antibody immunoblot will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody cell binding assay (CBA) and GFAP antibody IFA titer will be performed at an additional charge.
If the collapsin response-mediator protein-5 (CRMP-5)-IgG antibody Western blot is positive, then CRMP-5-IgG antibody IF titer will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta 2 (AP3B2) antibody, then AP3B2 antibody IFA titer and AP3B2 antibody CBA will be performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then alpha internexin CBA NIF heavy chain CBA, NIF light chain CBA, and NIF IFA titer will be performed at an additional charge.
If the IFA patterns suggest antineuronal nuclear antibody type 1 (ANNA-1), then ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-3 antibody, then ANNA-3 IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then PCA-1 antibody IFA titer and PCA-1 antibody immunoblot will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then PCA-2 antibody IFA titer will be performed at an additional charge.
If the IFA patterns suggest amphiphysin antibody, then amphiphysin antibody IFA titer and amphiphysin antibody immunoblot will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then GFAP antibody cell binding assay (CBA) and GFAP antibody IFA titer will be performed at an additional charge.
If the collapsin response-mediator protein-5 (CRMP-5)-IgG antibody Western blot is positive, then CRMP-5-IgG antibody IF titer will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta 2 (AP3B2) antibody, then AP3B2 antibody IFA titer and AP3B2 antibody CBA will be performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then alpha internexin CBA NIF heavy chain CBA, NIF light chain CBA, and NIF IFA titer will be performed at an additional charge.
Preferred Specimen
4 mL serum from a red tube
Patient Preparation
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
2. This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Minimum Volume
2 mL
Other Acceptable Specimens
Serum gel tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 28 days
Frozen: 28 days
Ambient: 72 hours
Frozen: 28 days
Ambient: 72 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Gross lipemia: Reject
Gross icterus: Reject
Methodology
APBCS, CS2CS, LG1CS, AINCS, NFLCS, NFHCS, GFACS: Cell Binding Assay (CBA)
AGN1S, AGNTS, AMPHS, APHTS, ANN1S, AN1TS, ANN3S, AN3TS, APBIS, APBTS, NIFIS, NIFTS, PCABP, PCAB2, PC1TS, PC2TS, GFAIS, GFATS, CRMTS: Indirect Immunofluorescence Assay (IFA)
CRMWS; Western Blot (WB)
AGNBS, AMIBS, AN1BS, PC1BS, AN2BS: Immunoblot (IB)
FDA Status
Approved
Setup Schedule
Profile tests: Monday through Sunday; Reflex tests: Varies
Report Available
8-12 days
Limitations
Negative results do not exclude the possibility of a cancer diagnosis.
Intravenous immunoglobulin treatment prior to the serum collection may cause a false-positive result.
Intravenous immunoglobulin treatment prior to the serum collection may cause a false-positive result.
Reference Range
Included with report
Clinical Significance
Evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer
Directing a focused search for cancer
Investigating neurological symptoms that appear during, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Detecting early evidence of cancer recurrence in previously seropositive patients
Directing a focused search for cancer
Investigating neurological symptoms that appear during, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Detecting early evidence of cancer recurrence in previously seropositive patients
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum
